Identification of protein-coding genes regulated by differential DNA methylation enhancer regions in glioblastoma

doi:10.3969/j.issn.1006-7795.2022.01.019

Abstract

Abstract: Objective By integrating and analyzing DNA methylation data and expression data in glioblastoma (GBM), we identified protein-coding genes (PCGs) that might be regulated by differential DNA methylation enhancer regions (DMERs) in GBM, predicted the biological functions of PCGs regulated by DMERs in GBM, and explored the potential biomarkers related to the GBM prognosis. Methods Based on methylation data and expression data in public disease databases, we used a computational strategy to construct genome-wide enhancer regions and screened for DMERS in GBM. We identified PCGs whose expression might be regulated by DMERs and performed enrichment analysis on these PCGs. Based on the patient's clinical information and the expression data of the corresponding samples, we performed Kaplan-Meier prognostic analysis on the identified PCGs. Results We screened 16 287 DMERs and identified 795 pairs of DMER-PCGs in this study, including 593 hypomethylated enhancers, 82 hypermethylated enhancers and 642 PCGs. We excavated 45 PCGs that were significantly related to the overall survival of GBM. Conclusion This study has further deepened the understanding of the regulatory pattern of enhancer methylation in GBM, and provided assistance for the development of novel biomarkers and targets for diagnosis and treatment of GBM.

Key words: glioblastoma, DNA methylation, enhancer region, epigenetic regulation, risk markers

CLC Number:

R739.41

Zhao Xiaoxiao, Yu Qiuhong, Ji Jianghuai, Wang Shijia, Wang Rendong, Li Dongguo. Identification of protein-coding genes regulated by differential DNA methylation enhancer regions in glioblastoma[J]. Journal of Capital Medical University, 2022, 43(1): 113-119.

0
/ / Recommend

Add to citation manager EndNote|Reference Manager|ProCite|BibTeX|RefWorks

URL: https://journal03.magtech.org.cn/Jweb_sdykdxxb/EN/10.3969/j.issn.1006-7795.2022.01.019

https://journal03.magtech.org.cn/Jweb_sdykdxxb/EN/Y2022/V43/I1/113

References

[1] Louis D N, Perry A, Reifenberger G, et al. The 2016 world health organization classification of tumors of the central nervous system: a summary[J]. Acta Neuropathol, 2016, 131(6): 803-820.
[2] Ahir B K, Engelhard H H, Lakka S S. Tumor development and angiogenesis in adult brain tumor: glioblastoma[J]. Mol Neurobiol, 2020, 57(5): 2461-2478.
[3] Prados M D, Byron S A, Tran N L, et al. Toward precision medicine in glioblastoma: the promise and the challenges[J]. Neuro Oncol, 2015, 17(8): 1051-1063.
[4] Lee E, Yong R L, Paddison P, et al. Comparison of glioblastoma (GBM) molecular classification methods[J]. Semin Cancer Biol, 2018, 53: 201-211.
[5] Stackhouse C T, Gillespie G Y, Willey C D. Exploring the roles of lncRNAs in GBM pathophysiology and their therapeutic potential[J]. Cells, 2020, 9(11): 2369.
[6] Wang Z H, Guo X P, Gao L, et al. Glioblastoma cell differentiation trajectory predicts the immunotherapy response and overall survival of patients[J]. Aging, 2020, 12(18): 18297-18321.
[7] Mahmoud A M, Ali M M. Methyl donor micronutrients that modify DNA methylation and cancer outcome[J]. Nutrients, 2019, 11(3): 608.
[8] Morgan A E, Davies T J, Mc Auley M T. The role of DNA methylation in ageing and cancer[J]. Proc Nutr Soc, 2018, 77(4): 412-422.
[9] Ji J H, Zhao L, Zhao X X, et al. Genome-wide DNA methylation regulation analysis of long non-coding RNAs in glioblastoma[J]. Int J Mol Med, 2020, 46(1): 224-238.
[10] Chen X Y, Zhang M J, Gan H Y, et al. A novel enhancer regulates MGMT expression and promotes temozolomide resistance in glioblastoma[J]. Nat Commun, 2018, 9(1): 2949.
[11] Xia J H, Wei G H. Enhancer dysfunction in 3D genome and disease[J]. Cells, 2019, 8(10): 1281.
[12] Aran D, Sabato S, Hellman A. DNA methylation of distal regulatory sites characterizes dysregulation of cancer genes[J]. Genome Biol, 2013, 14(3): R21.
[13] Lin X Z, Li L, Liu X J, et al. Genome-wide analysis of aberrant methylation of enhancer DNA in human osteoarthritis[J]. BMC Med Genomics, 2020, 13(1): 1.
[14] Xiong L, Wu F, Wu Q, et al. Aberrant enhancer hypomethylation contributes to hepatic carcinogenesis through global transcriptional reprogramming[J]. Nat Commun, 2019, 10(1): 335.
[15] Harrow J, Frankish A, Gonzalez J M, et al. GENCODE: the reference human genome annotation for the ENCODE project[J]. Genome Res, 2012, 22(9): 1760-1774.
[16] Yosipof A, Senderowitz H. k-nearest neighbors optimization-based outlier removal[J]. J Comput Chem, 2015, 36(8): 493-506.
[17] Yao L J, Shen H, Laird P W, et al. Inferring regulatory element landscapes and transcription factor networks from cancer methylomes[J]. Genome Biol, 2015, 16(1): 105.
[18] Hnisz D, Abraham B J, Lee T I, et al. Super-enhancers in the control of cell identity and disease[J]. Cell, 2013, 155(4): 934-947.
[19] Sur I, Taipale J. The role of enhancers in cancer[J]. Nat Rev Cancer, 2016, 16(8): 483-493.
[20] Bell R E, Golan T, Sheinboim D, et al. Enhancer methylation dynamics contribute to cancer plasticity and patient mortality[J]. Genome Res, 2016, 26(5): 601-611.
[21] Zhang S M, Wang Y H, Gu Y, et al. Specific breast cancer prognosis-subtype distinctions based on DNA methylation patterns[J]. Mol Oncol, 2018, 12(7): 1047-1060.
[22] Zhang C L, Wang X Y, Li X C, et al. The landscape of DNA methylation-mediated regulation of long non-coding RNAs in breast cancer[J]. Oncotarget, 2017, 8(31): 51134-51150.
[23] Ritchie M E, Phipson B, Wu D, et al. Limma powers differential expression analyses for RNA-sequencing and microarray studies[J]. Nucleic Acids Res, 2015, 43(7): e47.
[24] Ferreira J A. The Benjamini-Hochberg method in the case of discrete test statistics[J]. Int J Biostat, 2007, 3(1): Article 11.
[25] Lettice L A, Heaney S J H, Purdie L A, et al. A long-range Shh enhancer regulates expression in the developing limb and fin and is associated with preaxial polydactyly[J]. Hum Mol Genet, 2003, 12(14): 1725-1735.
[26] Flam E L, Danilova L, Kelley D Z, et al. Differentially methylated super-enhancers regulate target gene expression in human cancer[J]. Sci Rep, 2019, 9(1): 15034.
[27] Yu G C, Wang L G, Han Y Y, et al. clusterProfiler: an R package for comparing biological themes among gene clusters[J]. OMICS, 2012, 16(5): 284-287.
[28] Zhou V W, Goren A, Bernstein B E. Charting histone modifications and the functional organization of mammalian genomes[J]. Nat Rev Genet, 2011, 12(1): 7-18.
[29] Qu Y, Siggens L, Cordeddu L, et al. Cancer-specific changes in DNA methylation reveal aberrant silencing and activation of enhancers in leukemia[J]. Blood, 2017, 129(7): e13-e25.
[30] Keller S, Schmidt M H H. EGFR and EGFRvIII promote angiogenesis and cell invasion in glioblastoma: combination therapies for an effective treatment[J]. Int J Mol Sci, 2017, 18(6): 1295.
[31] Lawn S, Krishna N, Pisklakova A, et al. Neurotrophin signaling via TrkB and TrkC receptors promotes the growth of brain tumor-initiating cells[J]. J Biol Chem, 2015, 290(6): 3814-3824.
[32] Bates S E. Epigenetic therapies for cancer[J]. N Engl J Med, 2020, 383(7): 650-663.
[33] Greenberg M V C, Bourc'his D. The diverse roles of DNA methylation in mammalian development and disease[J]. Nat Rev Mol Cell Biol, 2019, 20(10): 590-607.
[34] Binabaj M M, Bahrami A, ShahidSales S, et al. The prognostic value of MGMT promoter methylation in glioblastoma: a meta-analysis of clinical trials[J]. J Cell Physiol, 2018, 233(1): 378-386.
[35] Jia D Y, Lin W, Tang H L, et al. Integrative analysis of DNA methylation and gene expression to identify key epigenetic genes in glioblastoma[J]. Aging, 2019, 11(15): 5579-5592.
[36] Huber R M, Rajski M, Sivasankaran B, et al. Deltex-1 activates mitotic signaling and proliferation and increases the clonogenic and invasive potential of U373 and LN18 glioblastoma cells and correlates with patient survival[J]. Plos One, 2013, 8(2): e57793.
[37] Tian L Q, Liu E Q, Zhu X D, et al. MicroRNA-197 inhibits cell proliferation by targeting GAB2 in glioblastoma[J]. Mol Med Rep, 2016, 13(5): 4279-4288.
[38] Dai D W, Lu Q, Wang L X, et al. Decreased miR-106a inhibits glioma cell glucose uptake and proliferation by targeting SLC2A3 in GBM[J]. BMC Cancer, 2013, 13: 478.